WEDNESDAY, Sept. 16 (HealthDay News) -- Lipid screening in survivors of Hodgkin's lymphoma who receive mediastinal irradiation, which increases their risk of coronary heart disease, is most cost effective if done every three years, according to a study published online Sept. 14 in the Journal of Clinical Oncology.
Aileen B. Chen, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues developed a model to evaluate the cost-effectiveness and optimal lipid screening interval in a hypothetical group of 30-year-old survivors of Hodgkin's lymphoma who had survived for five years following mediastinal irradiation.
The researchers found that lipid screening at any interval up to seven years was cost effective compared with no screening, using an incremental cost-effectiveness ratio threshold of $100,000 per quality-adjusted life-year saved. Screening at three-year intervals was most cost effective. The optimal screening interval was most affected by the risk of cardiac events or death and the efficacy and costs of statins.
"Lipid screening in survivors of Hodgkin's lymphoma, with statin therapy for screen-positive patients, improves survival and is cost effective," Chen and colleagues conclude. "A screening interval of three years seems reasonable in the long-term follow-up of survivors of Hodgkin's lymphoma."
Copyright © 2009 ScoutNews, LLC. All rights reserved.
|Previous: Diabetes Treatments May Not Reduce Inflammatory Markers||Next: Lymphoma Death Risk Higher in Rural Area, Local Provider|
Reader comments on this article are listed below. Review our comments policy.